Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease With Evidence of Mucosal Ulceration

Next Previous
Trial Profile

Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease With Evidence of Mucosal Ulceration

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms FITZROY
  • Sponsors Galapagos NV

Most Recent Events

  • 01 Aug 2022 Results assessing effects of JAK1-Preferential Inhibitor Filgotinib on circulating biomarkers and whole blood Genes/Pathways using data from this study published in the Inflammatory Bowel Diseases
  • 19 May 2020 Results, analysis of baseline correlation of whole blood transcriptome pathway activities with clinical disease indexes and circulating cytokines, published in Gastroenterology in conjunction with Digestive Disease Week 2020
  • 19 May 2020 Results of poct-hoc analysis assessing the effect of FIL on molecular markers of JAK1-related signalling (STAT1 & STAT3 phosphorylation) within epithelium and non-epithelium regions of intestinal mucosa and explore their correlation to histologic and endoscopic indices published at the Digestive Disease Week 2020

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top